David Schwindt
Adolescent Medicine · Mystic, CTNPI 1366489536
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Among adolescent medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $42.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AbbVie$910
- AstraZeneca$546
- Saluda Medical Americas, Inc.$277
- Amarin Pharma, Inc.$230
- Johnson & Johnson$201
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,71399%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 18 | $1,093 |
| AbbVie(2 entities) | 37 | $910 |
| AstraZeneca | 8 | $546 |
| Saluda Medical Americas, Inc. | 2 | $277 |
| Amarin Pharma, Inc. | 12 | $230 |
| Johnson & Johnson | 2 | $201 |
| Novo Nordisk | 5 | $189 |
| Boehringer Ingelheim | 4 | $163 |
| Otsuka America Pharmaceutical, Inc. | 2 | $157 |
| Madrigal Pharmaceuticals | 1 | $128 |
| Nevro Corp. | 1 | $122 |
| Boston Scientific | 1 | $119 |
| Vertos Medical, Inc. | 1 | $89 |
| Abbott | 1 | $85 |
| Stryker | 1 | $78 |
| Axsome Therapeutics, Inc. | 1 | $74 |
| Lilly USA, LLC | 3 | $66 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| Merck | 3 | $53 |
| Coloplast | 1 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| IBSA Pharma Inc. | 1 | $19 |
| Exact Sciences | 1 | $17 |
| Verona Pharma, Inc. | 1 | $16 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,756 in reported general payments places this provider in the 95th percentile of 57 adolescent medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $23,585 |
| MyrbetriqMirabegron | 22 | $17,498 |
| LinzessLinaclotide | 28 | $16,323 |
| JardianceEmpagliflozin | 18 | $13,451 |
| VascepaIcosapent Ethyl | 23 | $9,783 |
| Nebivolol Hcl | 93 | $5,552 |
| Fentanyl | 20 | $2,891 |
| Rosuvastatin Calcium | 176 | $2,738 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,125 |
| Omega-3 Acid Ethyl Esters | 29 | $1,518 |
| PaxlovidNirmatrelvir/Ritonavir | 22 | $1,429 |
| Ezetimibe | 46 | $1,258 |
| Gabapentin | 31 | $891 |
| Olmesartan Medoxomil | 62 | $871 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $14 | $25,01436 claims |
| AbbVieLinzess, Synthroid, Armour Thyroid | $910 | $17,32855 claims |
| Boehringer IngelheimJardiance | $163 | $13,45118 claims |
| GSKArnuity Ellipta | $1,093 | $2,12512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 adolescent medicine providers in Connecticut.
Other adolescent medicine in Mystic
- Husam ShitiaCheshire$7K
- Ramani YapaHamden$4K
- Nicholas MongilloShelton$2K
- Hikmat ShaarbafWallingford$2K
- Debbie CayabyabWaterbury$2K
- Fadi HammoudShelton$2K
- George TsimoyianisDarien$2K
- Adam KatzWilton$1K
- Lori Storch SmithWestport$1K
- Carol GormanWestport$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.